-Ching-Lung Lai Researcher Activity Profile

Research Author Detailed Information 

Ching-Lung Lai Publication Rate By Year

Ching-Lung Lai has published 1 paper(s) in 1988, 1 paper(s) in 2003, 2 paper(s) in 2006, 29 paper(s) in 2007, 5 paper(s) in 2008, for a total of 38 research publications in total.

Ching-Lung Cl Lai Author Information

LAST NAME: lai

FIRST NAME: Ching-Lung

INITIALS: cl

AFFILIATION:

Papers

Ching-Lung Lai's Publication Record

1. Two subtypes (subgenotypes) of hepatitis B virus genotype C: A novel subtyping assay based on restriction fragment length polymorphism. Year Published: 2006
Department of Clinical Molecular Informative Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
2. A case-control study of response to lamivudine therapy for 2 years in Japanese and Chinese patients chronically infected with hepatitis B virus of genotypes Bj, Ba and C. Year Published: 2006
Department of Internal Medicine and Molecular Science, Nagoya City University Graduate School of Medical Sciences, Kawasumi 1, Mizuho, Nagoya 467-8601, Japan.
3. Quantitative analysis of HBV cccDNA from clinical specimens: correlation with clinical and virological response during antiviral therapy. Year Published: 2007
Discovery Virology Department, GlaxoSmithKline, Research Triangle Park, NC 27709, USA.
4. Low serum HBV DNA levels and development of hepatocellular carcinoma in patients with chronic hepatitis B: a case-control study. Year Published: 2007
Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong.
5. Correlation between white blood cell count and metabolic syndrome in adolescence. Year Published: 2007
Division of Endocrinology and Metabolism, Department of Internal Medicine, Tri-Service General Hospital, Taipei, Taiwan.
6. The natural history of chronic hepatitis B. Year Published: 2007
Department of Medicine, The University of Hong Kong, Hong Kong. hrmelcl@hkucc.hku.hk
7. Evolution of primary and compensatory lamivudine resistance mutations in chronic hepatitis B virus-infected patients during long-term lamivudine treatment, assessed by a line probe assay. Year Published: 2007
Innogenetics NV, Industriepark Zwijnaarde 7/4, B-9052, Ghent, Belgium.
8. Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection. Year Published: 2007
Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam Road, Hong Kong SAR, China.
9. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Year Published: 2007
The Chinese University of Hong Kong, Shatin, Hong Kong, China. hlychan@cuhk.edu.hk
10. Giant cell arteritis with multiple cranial nerve palsy and reversible proptosis: a case report. Year Published: 2007
Department of Neurology, Kaohsiung Municipal Hsiaokang Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
11. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Year Published: 2007
Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong, China.
12. Evolution of Primary and Compensatory Lamivudine Resistance Mutations in Chronic Hepatitis B Virus-Infected Patients during Long-Term Lamivudine Treatment, Assessed by a Line Probe Assay. Year Published: 2007
Innogenetics N.V., Industriepark Zwijnaarde 7/4, B-9052 Ghent, Belgium. fred_shapiro@innogenetics.com.
13. Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection. Year Published: 2007
Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam Road, Hong Kong SAR, China. mfyuen@hkucc.hku.hk.
14. Association of apolipoprotein e polymorphism with ischemic stroke subtypes in taiwan. Year Published: 2007
Department of Neurology, Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung Medical University, and Department of Neurology, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
15. Association of apolipoprotein E polymorphism with ischemic stroke subtypes in Taiwan. Year Published: 2007
Department of Neurology, Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
16. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Year Published: 2007
The Chinese University of Hong Kong, Shatin, Hong Kong, China. hlychan@cuhk.edu.hk
17. Precore and core promoter mutations at the time of HBeAg seroclearance in Chinese patients with chronic hepatitis B. Year Published: 2007
Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam Road, Hong Kong, PR China.
18. Low serum HBV DNA levels and development of hepatocellular carcinoma in patients with chronic hepatitis B: a case-control study. Year Published: 2007
Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong.
19. Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels. Year Published: 2007
Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam Road, Hong Kong. mfyuen@hkucc.hku.hk
20. Telbivudine versus lamivudine in patients with chronic hepatitis B. Year Published: 2007
University Department of Medicine, Queen Mary Hospital, Hong Kong, China. hrmelcl@hkucc.hku.hk
21. Mutational analysis of 65 Wilson disease patients in Hong Kong Chinese: Identification of 17 novel mutations and its genetic heterogeneity. Year Published: 2007
Department of Chemical Pathology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong, China, ching-wanlam@cuhk.edu.hk.
22. Telbivudine versus lamivudine in patients with chronic hepatitis B. Year Published: 2007
University Department of Medicine, Queen Mary Hospital, Hong Kong, China. hrmelcl@hkucc.hku.hk
23. Association of apolipoprotein E polymorphism with ischemic stroke subtypes in Taiwan. Year Published: 2007
Department of Neurology, Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
24. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Year Published: 2007
Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong, China.
25. Evolution of primary and compensatory lamivudine resistance mutations in chronic hepatitis B virus-infected patients during long-term lamivudine treatment, assessed by a line probe assay. Year Published: 2007
Innogenetics NV, Industriepark Zwijnaarde 7/4, B-9052, Ghent, Belgium.
26. Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection. Year Published: 2007
Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam Road, Hong Kong SAR, China.
27. Giant cell arteritis with multiple cranial nerve palsy and reversible proptosis: a case report. Year Published: 2007
Department of Neurology, Kaohsiung Municipal Hsiaokang Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
28. Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels. Year Published: 2007
Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam Road, Hong Kong. mfyuen@hkucc.hku.hk
29. Sucralfate versus cimetidine in duodenal ulcer--factors affecting healing and relapse. Year Published: 1988
University Department of Medicine, Queen Mary Hospital, Hong Kong.
30. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Year Published: 2008
Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong.
31. Correlation between white blood cell count and metabolic syndrome in adolescence. Year Published: 2007
Division of Endocrinology and Metabolism, Department of Internal Medicine, Tri-Service General Hospital, Taipei, Taiwan.
32. Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples. Year Published: 2008
Division of Hematology-Oncology, Chang Gung Memorial Hospital, Taipei, Taiwan.
33. The natural history of chronic hepatitis B. Year Published: 2007
Department of Medicine, The University of Hong Kong, Hong Kong. hrmelcl@hkucc.hku.hk
34. Apolipoprotein E in Taiwan Chinese patients with dementia. Year Published: 2003
Department of Neurology, Kaohsiung Medical University, Kaohsiung, Taiwan.
35. Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples. Year Published: 2008
Division of Hematology-Oncology, Chang Gung Memorial Hospital, Taipei, Taiwan.
36. Giant cell arteritis with multiple cranial nerve palsy and reversible proptosis: a case report. Year Published: 2007
Department of Neurology, Kaohsiung Municipal Hsiaokang Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
37. What is the best end point for hepatitis B treatment? Year Published: 2008
the University of Hong Kong, Queen Mary Hospital, Hong Kong, China.
38. What is the best end point for hepatitis B treatment? Year Published: 2008